Home Newsfeeds B of A Securities Upgrades Flowserve to Neutral

B of A Securities Upgrades Flowserve to Neutral

B of A Securities analyst Andrew Obin upgrades Flowserve (NYSE:FLS) from Underperform to Neutral.

byBenzinga Newsdesk

July 11, 2022

1 minute read

B of A Securities analyst Andrew Obin upgrades Flowserve (NYSE:FLS) from Underperform to Neutral.

Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting

By Benzinga Newsdesk

November 9, 12:08 PM

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of two ePosters at

PHVS

Ford’s 2022 Mach-E Recall Of 49,000 Units Investigated By US

By Nabaparna Bhattacharya

August 21, 10:41 AM

Ford Motor Company's (NYSE: F) recall of nearly 49,000 Ford Mustang Mach-E electric vehicles last year is reportedly being investigated by the U.S. auto safety regulators to understand if the company had adequately addressed concerns.

News
Tech

iPhone App Sideloading: Apple Gears Up To Charge Fees For Apps Downloaded Outside Of App Store

By Rounak Jain

January 24, 10:14 AM

Apple is reportedly planning to implement fees and restrictions for apps downloaded outside of its App Store.

AAPL

News

Verve Therapeutics Announces Updates On PCSK9 Program, Company To Pause Enrollment In Heart-1 Clinical Trial Following Asymptomatic Grade 3 Transient Alt Elevation And Thrombocytopenia Seen In Sixth Participant Enrolled In 0.45 Mg/Kg Dose Cohort

By Benzinga Newsdesk

April 2, 7:08 AM

VERVE-101 is being evaluated in the Heart-1 Phase 1b clinical trial with trial endpoints of safety and tolerability as well as changes in blood PCSK9 protein and low-density lipoprotein cholesterol (LDL-C) levels in

VERV

B of A Securities Upgrades Flowserve to Neutral

Related Posts

Pharvaris Presents Deucrictibant Clinical Data And Real-World HAE Treatment Satisfaction Data At ACAAI 2023 Annual Scientific Meeting

Ford’s 2022 Mach-E Recall Of 49,000 Units Investigated By US

iPhone App Sideloading: Apple Gears Up To Charge Fees For Apps Downloaded Outside Of App Store

Verve Therapeutics Announces Updates On PCSK9 Program, Company To Pause Enrollment In Heart-1 Clinical Trial Following Asymptomatic Grade 3 Transient Alt Elevation And Thrombocytopenia Seen In Sixth Participant Enrolled In 0.45 Mg/Kg Dose Cohort